8-K: Predictive Oncology Secures Up to $10 Million Equity Line for Working Capital

Predictive Oncology Inc. has entered into a Standby Equity Purchase Agreement with YA II PN, LTD., providing the company access to up to $10 million in equity financing for general corporate purposes.

Summary

• Predictive Oncology Inc. (the Company) entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD. (the Investor) on July 1, 2025.
• The SEPA allows the Company to sell up to $10 million of its common stock to the Investor over a 36-month period.
• Shares will be purchased at 96% of the lowest daily Volume Weighted Average Price (VWAP) during the three consecutive trading days commencing on the Advance Notice date, with the Company having the option to set a minimum acceptable price.
• The Company paid the Investor a $25,000 structuring fee and issued 120,482 shares of common stock as a 1.00% commitment fee (valued at $100,000 based on the $10 million commitment).
• Proceeds from the sales are intended for working capital and general corporate purposes.
• The agreement includes an "Exchange Cap" limiting sales to 1,921,706 shares (19.99% of outstanding shares as of the SEPA effective date) unless shareholder approval is obtained or the average sale price exceeds $0.83 per share.
• The Investor's beneficial ownership is capped at 4.99% of the Company's then outstanding voting power or common shares.
• The Company must prepare and file a registration statement(s) with the SEC for resale of shares to the Investor, and cannot request advances until such registration statement(s) become effective.

Sentiment

Score: 6

Explanation: The agreement provides a flexible source of capital, which is positive for liquidity and operational continuity. However, it comes with significant potential for shareholder dilution and a discount on share sales, which are negative aspects. The overall sentiment is cautiously positive as it addresses a funding need but at a cost to existing shareholders.

Positives

• Secures access to up to $10 million in equity capital, providing financial flexibility and liquidity for general corporate purposes.
• The Company retains discretion on when and if to request advances, allowing it to manage timing based on market conditions and capital needs.
• The ability to establish a "Minimum Acceptable Price" helps protect against selling shares at excessively low valuations.
• There are no mandatory minimum advances or non-usage fees, offering flexibility without penalty for non-utilization of the full commitment.

Negatives

• The equity line facility will result in significant dilution for existing shareholders as new shares are issued over time.
• Shares are sold at a 4% discount (96% of VWAP), which is below the prevailing market price.
• The commitment fee of 120,482 shares and a $25,000 structuring fee represent immediate costs and dilution to the Company.
• The "Exchange Cap" and "Ownership Limitation" may restrict the Company's ability to fully utilize the $10 million commitment without further shareholder approval or if the stock price remains low.

Risks

• Dilution Risk: Issuance of new common shares will dilute the ownership interest of existing shareholders.
• Share Price Volatility: The actual proceeds received will depend on the frequency and prices at which shares are sold, which are subject to market fluctuations.
• Regulatory Compliance Risk: The Company must maintain an effective registration statement and comply with Nasdaq rules (e.g., Exchange Cap, $0.83 price threshold) to utilize the facility, failure of which could limit access to funds.
• Market Perception Risk: Equity lines can sometimes be perceived negatively by the market, potentially putting downward pressure on the stock price.
• Operational Risk: Proceeds are for "working capital and general corporate purposes," which is broad and doesn't specify high-impact strategic initiatives, implying a need for general operational funding.

Future Outlook

The Company expects to use any proceeds received from sales under the SEPA for working capital and general corporate purposes. The agreement provides a flexible financing option for future operational needs over the next three years.

Management Comments

• The Company expects that any proceeds received from such sales to the Investor will be used for working capital and general corporate purposes.
• The Company is aware and acknowledges that issuance of Common Shares hereunder could cause dilution to existing shareholders and could significantly increase the outstanding number of Common Shares.

Industry Context

This type of "equity line" or "standby equity purchase agreement" is a common financing mechanism for smaller public companies, particularly those in growth phases or with fluctuating capital needs, such as biotech or early-stage technology firms. It provides a flexible, "at-the-market" funding source without the immediate upfront dilution or fixed obligations of traditional debt or firm commitment equity offerings. It is often used when companies need access to capital but want to control the timing and amount of share issuances based on market conditions and their capital requirements.

Comparison to Industry Standards

• The 4% discount to VWAP (96% of VWAP) is a common pricing structure for such equity lines, reflecting the liquidity and flexibility provided by the investor.
• The 19.99% "Exchange Cap" is standard for Nasdaq-listed companies to avoid triggering shareholder approval requirements for issuances exceeding 20% of outstanding shares.
• The 4.99% beneficial ownership limitation for the investor is also standard to avoid triggering beneficial ownership reporting requirements (e.g., Schedule 13D filings) and potential "control" implications.
• The $25,000 structuring fee and 1% commitment fee (paid in shares) are typical costs associated with establishing such facilities, compensating the investor for their commitment and administrative efforts.
• The 36-month term is a common duration for these types of flexible financing agreements.

Stakeholder Impact

• Shareholders: Will experience dilution as new shares are issued under the agreement. The value of existing shares may be negatively impacted by the increased share count and the discount at which new shares are sold.
• Company Operations: Provides a flexible source of capital for working capital and general corporate purposes, supporting ongoing operations and potential growth initiatives.
• Creditors: Access to equity capital can strengthen the company's balance sheet, potentially improving its credit profile.

Next Steps

• The Company must prepare and file a registration statement(s) with the SEC to register the shares for resale by the Investor.
• The Company cannot request any advances until the registration statement(s) become effective.
• The Company will use proceeds for working capital and general corporate purposes.
• The Company will maintain the effectiveness of the registration statement during the commitment period.

Key Dates

Recommendation

Keywords

Predictive Oncology, POAI, Standby Equity Purchase Agreement, SEPA, Equity Line, Capital Raise, Dilution, SEC Filing, Form 8-K, YA II PN LTD, Nasdaq Capital Market, Working Capital, Financing, Common Stock